+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Glaucoma Treatment Market Research Report by Indication (Angle Closure Glaucoma, Congenital Glaucoma, and Open Angle Glaucoma), Type, Sales Channel, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 147 Pages
  • July 2022
  • Region: United States
  • 360iResearch™
  • ID: 5367981
UP TO OFF until Dec 31st 2022
The United States Glaucoma Treatment Market size was estimated at USD 1,485.52 million in 2021, USD 1,589.57 million in 2022, and is projected to grow at a CAGR 8.21% to reach USD 2,386.24 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Glaucoma Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Indication, the market was studied across Angle Closure Glaucoma, Congenital Glaucoma, Open Angle Glaucoma, and Secondary Glaucoma.
  • Based on Type, the market was studied across Alpha Agonist, Beta Blockers, Carbonic Anhydrase Inhibitors, Cholinergic, Combined Medications, and Prostaglandin Analogs.
  • Based on Sales Channel, the market was studied across Hospital Pharmacies, Online Sales, and Retail Pharmacies.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Glaucoma Treatment market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Glaucoma Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Glaucoma Treatment Market, including AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn, Inc., Alcon Inc., Asico, LLC, Carl Zeiss Meditec AG, Fera Pharmaceuticals, LLC, Glaukos Corporation, Lumenis Be Ltd., Nidek Co., Ltd., Novartis International AG, Ocular Therapeutix, Inc., Perrigo Company PLC, Pfizer Inc., Santen Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Glaucoma Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Glaucoma Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Glaucoma Treatment Market?
4. What is the competitive strategic window for opportunities in the United States Glaucoma Treatment Market?
5. What are the technology trends and regulatory frameworks in the United States Glaucoma Treatment Market?
6. What is the market share of the leading vendors in the United States Glaucoma Treatment Market?
7. What modes and strategic moves are considered suitable for entering the United States Glaucoma Treatment Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Research and Development (R&D) in Cell and Molecular Biology in Glaucoma Treatment
5.1.1.2. Rising Prevalence Of Glaucoma and its Growing Awareness among The Population
5.1.2. Restraints
5.1.2.1. Various Instances of Product Recalls by Significant Market Players
5.1.3. Opportunities
5.1.3.1. Growing Early Diagnosis Rate Combined with Developing Novel Therapy for the Glaucoma eye
5.1.3.2. Research and Development (R&D) in Cell and Molecular Biology in Glaucoma Treatment
5.1.4. Challenges
5.1.4.1. Limitation Associated with the Availability of any Definitive Glaucoma Treatment
5.2. Cumulative Impact of COVID-19
6. Glaucoma Treatment Market, by Indication
6.1. Introduction
6.2. Angle Closure Glaucoma
6.3. Congenital Glaucoma
6.4. Open Angle Glaucoma
6.5. Secondary Glaucoma
7. Glaucoma Treatment Market, by Type
7.1. Introduction
7.2. Alpha Agonist
7.3. Beta Blockers
7.4. Carbonic Anhydrase Inhibitors
7.5. Cholinergic
7.6. Combined Medications
7.7. Prostaglandin Analogs
8. Glaucoma Treatment Market, by Sales Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Sales
8.4. Retail Pharmacies
9. California Glaucoma Treatment Market10. Florida Glaucoma Treatment Market11. Illinois Glaucoma Treatment Market12. New York Glaucoma Treatment Market13. Ohio Glaucoma Treatment Market14. Pennsylvania Glaucoma Treatment Market15. Texas Glaucoma Treatment Market
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. AbbVie Inc.
17.2. Aerie Pharmaceuticals Inc.
17.3. Akorn, Inc.
17.4. Alcon Inc.
17.5. Asico, LLC
17.6. Carl Zeiss Meditec AG
17.7. Fera Pharmaceuticals, LLC
17.8. Glaukos Corporation
17.9. Lumenis Be Ltd.
17.10. Nidek Co., Ltd.
17.11. Novartis International AG
17.12. Ocular Therapeutix, Inc.
17.13. Perrigo Company PLC
17.14. Pfizer Inc.
17.15. Santen Pharmaceutical Co., Ltd.
17.16. Teva Pharmaceutical Industries Ltd.
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES GLAUCOMA TREATMENT MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2027
FIGURE 7. UNITED STATES GLAUCOMA TREATMENT MARKET DYNAMICS
FIGURE 8. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2027
FIGURE 11. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY ANGLE CLOSURE GLAUCOMA, 2019-2027 (USD MILLION)
FIGURE 12. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY ANGLE CLOSURE GLAUCOMA, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 13. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY CONGENITAL GLAUCOMA, 2019-2027 (USD MILLION)
FIGURE 14. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY CONGENITAL GLAUCOMA, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY OPEN ANGLE GLAUCOMA, 2019-2027 (USD MILLION)
FIGURE 16. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY OPEN ANGLE GLAUCOMA, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SECONDARY GLAUCOMA, 2019-2027 (USD MILLION)
FIGURE 18. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SECONDARY GLAUCOMA, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 19. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 20. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2027
FIGURE 22. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY ALPHA AGONIST, 2019-2027 (USD MILLION)
FIGURE 23. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY ALPHA AGONIST, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 24. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY BETA BLOCKERS, 2019-2027 (USD MILLION)
FIGURE 25. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY BETA BLOCKERS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 26. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 27. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 28. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY CHOLINERGIC, 2019-2027 (USD MILLION)
FIGURE 29. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY CHOLINERGIC, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 30. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY COMBINED MEDICATIONS, 2019-2027 (USD MILLION)
FIGURE 31. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY COMBINED MEDICATIONS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 32. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY PROSTAGLANDIN ANALOGS, 2019-2027 (USD MILLION)
FIGURE 33. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 34. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2021 VS 2027 (%)
FIGURE 35. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2021 VS 2027 (USD MILLION)
FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2027
FIGURE 37. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2019-2027 (USD MILLION)
FIGURE 38. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 39. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY ONLINE SALES, 2019-2027 (USD MILLION)
FIGURE 40. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY ONLINE SALES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 41. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2019-2027 (USD MILLION)
FIGURE 42. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 43. CALIFORNIA GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 44. FLORIDA GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 45. ILLINOIS GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. NEW YORK GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. OHIO GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. PENNSYLVANIA GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. TEXAS GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. UNITED STATES GLAUCOMA TREATMENT MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 51. UNITED STATES GLAUCOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 52. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES GLAUCOMA TREATMENT MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES GLAUCOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 5. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY ANGLE CLOSURE GLAUCOMA, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY CONGENITAL GLAUCOMA, BY STATE, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY OPEN ANGLE GLAUCOMA, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SECONDARY GLAUCOMA, BY STATE, 2019-2027 (USD MILLION)
TABLE 10. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY ALPHA AGONIST, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY BETA BLOCKERS, BY STATE, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY CHOLINERGIC, BY STATE, 2019-2027 (USD MILLION)
TABLE 15. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY COMBINED MEDICATIONS, BY STATE, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 19. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY ONLINE SALES, BY STATE, 2019-2027 (USD MILLION)
TABLE 20. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 21. CALIFORNIA GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 22. CALIFORNIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2019-2027 (USD MILLION)
TABLE 23. CALIFORNIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 24. CALIFORNIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2019-2027 (USD MILLION)
TABLE 25. FLORIDA GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 26. FLORIDA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2019-2027 (USD MILLION)
TABLE 27. FLORIDA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 28. FLORIDA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2019-2027 (USD MILLION)
TABLE 29. ILLINOIS GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 30. ILLINOIS GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2019-2027 (USD MILLION)
TABLE 31. ILLINOIS GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 32. ILLINOIS GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2019-2027 (USD MILLION)
TABLE 33. NEW YORK GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 34. NEW YORK GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2019-2027 (USD MILLION)
TABLE 35. NEW YORK GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 36. NEW YORK GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2019-2027 (USD MILLION)
TABLE 37. OHIO GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 38. OHIO GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2019-2027 (USD MILLION)
TABLE 39. OHIO GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 40. OHIO GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2019-2027 (USD MILLION)
TABLE 41. PENNSYLVANIA GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 42. PENNSYLVANIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2019-2027 (USD MILLION)
TABLE 43. PENNSYLVANIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 44. PENNSYLVANIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2019-2027 (USD MILLION)
TABLE 45. TEXAS GLAUCOMA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 46. TEXAS GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2019-2027 (USD MILLION)
TABLE 47. TEXAS GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 48. TEXAS GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2019-2027 (USD MILLION)
TABLE 49. UNITED STATES GLAUCOMA TREATMENT MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 50. UNITED STATES GLAUCOMA TREATMENT MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 51. UNITED STATES GLAUCOMA TREATMENT MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 52. UNITED STATES GLAUCOMA TREATMENT MARKET RANKING
TABLE 53. UNITED STATES GLAUCOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2021
TABLE 54. UNITED STATES GLAUCOMA TREATMENT MARKET MERGER & ACQUISITION
TABLE 55. UNITED STATES GLAUCOMA TREATMENT MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 56. UNITED STATES GLAUCOMA TREATMENT MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 57. UNITED STATES GLAUCOMA TREATMENT MARKET INVESTMENT & FUNDING
TABLE 58. UNITED STATES GLAUCOMA TREATMENT MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 59. UNITED STATES GLAUCOMA TREATMENT MARKET: LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Aerie Pharmaceuticals Inc.
  • Akorn, Inc.
  • Alcon Inc.
  • Asico, LLC
  • Carl Zeiss Meditec AG
  • Fera Pharmaceuticals, LLC
  • Glaukos Corporation
  • Lumenis Be Ltd.
  • Nidek Co., Ltd.
  • Novartis International AG
  • Ocular Therapeutix, Inc.
  • Perrigo Company PLC
  • Pfizer Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...